Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rubella Susceptibility in Multiparous Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by St. Michael's Hospital, Toronto.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier:
NCT00401505
First received: November 17, 2006
Last updated: September 2, 2011
Last verified: December 2009
  Purpose

The purpose of this study is to determine the reasons why multiparous women (women who are pregnant and have been pregnant before) might still be susceptible to rubella.


Condition
Rubella
Vaccine

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Rubella Susceptibility in Multiparous Women

Resource links provided by NLM:


Further study details as provided by St. Michael's Hospital, Toronto:

Estimated Enrollment: 100
Study Start Date: September 2006
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:

This study is designed to investigate why multiparous women might still be susceptible to rubella. All pregnant women are checked for rubella immunity, and if they are non-immune, there are standard orders in our hospital to administer the rubella vaccine on the post-partum floor prior to discharge home from the hospital. Despite this, some multiparous women are found to be susceptible (non-immune), and this study will explore the reasons for this.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All rubella susceptible women who delivered during the study period.

Criteria

Inclusion Criteria:

  • All rubella susceptible women who delivered during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00401505

Locations
Canada, Ontario
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Investigators
Principal Investigator: Mark H Yudin, MD, MSc St. Michael's Hospital, Toronto
  More Information

No publications provided

Responsible Party: St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier: NCT00401505     History of Changes
Other Study ID Numbers: rubellain pregnancy
Study First Received: November 17, 2006
Last Updated: September 2, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by St. Michael's Hospital, Toronto:
rubella
rubella vaccine
postpartum
immunity

Additional relevant MeSH terms:
Disease Susceptibility
Rubella
Disease Attributes
Pathologic Processes
RNA Virus Infections
Rubivirus Infections
Togaviridae Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 27, 2014